BMY’s robust launch portfolio, resilient free cash flow, and above-consensus growth outlook position it for outsized returns ...

AEMD READ THE FULL AEMD RESEARCH REPORT Assessing if the Hemopurifier in conjunction with standard of care treatment can increase the population that can benefit from combined treatment Aethlon ...

Opdivo is used in adults to treat various cancers, including non-small cell lung cancer, melanoma, and classic Hodgkin’s lymphoma.For treating melanoma and a type of colorectal cancer, Opdivo ...

U.S. Food and Drug Administration Approves Opdivo ® (nivolumab) plus Yervoy ® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma. Based on the Phase 3 ...

Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The stock has also ...

PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

Opdivo, which is used to treat certain types of cancer, can cause side effects such as confusion. Learn about Opdivo’s side effects and how to manage them.

Bristol Myers Squibb (NYSE:BMY) announced Saturday that its checkpoint inhibitors Opdivo and Yervoy, when combined, reduced ...

Opdivo (nivolumab) is a brand-name IV infusion prescribed for some types of cancer in adults and certain children. As with other drugs, Opdivo can cause side effects, such as joint pain and fatigue.

Opdivo (nivolumab) is a brand-name IV infusion prescribed for non-small cell lung cancer (NSCLC) in some situations. This article covers topics such as side effects, dosage, and how Opdivo works.

Opdivo (nivolumab) and Opdivo Qvantig (nivolumab/hyaluronidase-nvhy) are a type of cancer treatment called immunotherapy. Immunotherapy works by using the body's immune system to fight cancer ...